The National Guidelines for Colorectal Cancer Screening and Diagnosis

Objectives

Establish a United Arab Emirates National Colorectal Cancer Screening Programme that sets minimum evidence-based standards for safe, quality-assured screening, diagnosis, referral, treatment pathways, documentation and reporting across all licensed providers, facilities, professionals and mobile units.[1][2][3]The programme aims to detect colorectal cancer and precursor lesions early, support timely follow-up, and deliver risk-stratified screening and surveillance for average-risk and higher-risk populations.[2][4][5]

• Screen eligible women and men aged 40 to 75 years; individualise decisions for those aged 76 to 85 years according to preferences, health status, life expectancy and previous screening.[2]
• Provide average-risk screening through colonoscopy every 10 years, offering annual faecal immunochemical testing when colonoscopy is declined.[6][7]
• Identify average, increased and high-risk individuals using age, personal and family history, inflammatory bowel disease, adenomas, sessile serrated polyps and hereditary colorectal cancer syndromes.[4][8]
• Apply risk-based surveillance intervals, ranging from no further surveillance or five-yearly colonoscopy for some low-risk adenomas to annual or three-month follow-up in specified high-risk circumstances.[8]
• Provide condition-specific surveillance for family-history groups, inflammatory bowel disease, hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, MUTYH-associated polyposis, Peutz-Jeghers syndrome and juvenile polyposis.[5][9]
• Maintain high-quality colonoscopy through adequate bowel preparation, complete examination, recorded inspection, withdrawal-time requirements, lesion detection, specimen handling and standardised reporting.[10][11]
• Ensure that people with normal, positive, unclear or spoilt results receive clear outcomes, repeat screening where appropriate, timely diagnostic referral and treatment pathways.[7]

Implementation

Deliver screening through licensed facilities and mobile units using coordinated clinical assessment, colonoscopy-led testing, laboratory-supported faecal immunochemical testing, multidisciplinary review, referral protocols and national registry reporting.[2][3]Implementation is supported by a national taskforce involving the Ministry of Health and Prevention, Department of Health Abu Dhabi, Dubai Health Authority, Emirates Health Services, public and private providers, and relevant oncology, gastroenterology and colorectal surgery specialists.[1]

• Recruit eligible people through targeted invitation systems, electronic or manual invitations, opportunistic consultations and health-promotion activities.[6]
• Appoint an accountable programme coordinator in each screening facility to oversee records, clinical performance indicators, referral coordination and submission of screening-visit and outcome data.[3]
• Assess risk at every screening visit and complete pre-colonoscopy assessment of demographics, relevant medicines, comorbidities, implanted devices, previous gastrointestinal procedures and American Society of Anesthesiology physical status.[3][6]
• Obtain and document informed consent, explain procedures and expected timelines, protect confidential records, and comply with federal requirements for information technology, electronic records, data management and result sharing.[2][3]
• Equip endoscopy units with appropriate patient-flow arrangements, recovery capacity, high-resolution video-endoscopy, accessories, resuscitation facilities, decontamination systems and infection-control arrangements.[4]
• Maintain policies for bowel preparation, sedation, patient comfort, positioning, infection control and anaesthesia support for people with significant comorbidities where required.[10]
• Operate laboratories with compliant identification, labelling and testing systems; follow manufacturer instructions for faecal immunochemical test kits; define and record haemoglobin cut-offs and results; and provide specialist support for genetic testing.[3]
• Use recognised laboratory accreditation, including College of American Pathologists, ISO 15189 or Joint Commission International accreditation, with potential independent quality-assurance testing commissioned by the Ministry of Health and Prevention.[3]
• Establish a colorectal cancer screening core team including at least two gastroenterologists and two trained nurses, with regular multidisciplinary meetings, staff training and evaluation aligned with international guidance.[4]
• Provide patients with clear faecal immunochemical test collection instructions, using one representative stool sample without dietary or drug restrictions, appropriate preservation and prompt analysis.[7]
• Refer positive faecal immunochemical test results for follow-up colonoscopy within 15 working days under one pathway and within 31 days under another specified standard.[7][4]
• Contact patients 24 hours after colonoscopy or on the next working day, provide discharge and adverse-event instructions, and track complications for 30 days.[11]
• Assign communication of colonoscopy results and next steps to the colonoscopist, and communication of faecal immunochemical test results to the referring physician.[7]
• Submit screening-visit data and outcomes to the National Cancer Screening Registry, and report confirmed screening-detected cancers to the National Cancer Registry, both at the Ministry of Health and Prevention.[2]
• Monitor participation, test adequacy, result turnaround, referral timeliness, caecal intubation, adenoma and cancer detection, withdrawal time, polyp retrieval, complications and time to definitive management.[12]
• Maintain auditable colonoscopy records, including completion images, procedure details, withdrawal times, instrument identification and adverse events; enable Ministry of Health and Prevention inspection and audit.[2][10]
• Meet specified quality thresholds, including inadequate bowel preparation in no more than 10% of examinations, unacceptable faecal immunochemical test samples in no more than 3% of kits received, and results delivered to more than 90% of participants within 15 working days.[6][10][7]
• Determine reimbursement eligibility under the Health Insurance Scheme according to the applicable insurance laws in each Emirate; programme budgets and funding allocations are not specified.[2][3][11]

Monitoring & Evaluation

The guideline establishes a national monitoring and accountability system for colorectal cancer screening, combining mandatory registry reporting, facility and laboratory audit, clinical performance indicators, documented follow-up, and Ministry of Health and Prevention oversight.[2][3][12]

• Submit screening-visit data and outcomes to the National Cancer Screening Registry at the Ministry of Health and Prevention, and report all confirmed screen-detected cancers to the National Cancer Registry.[2]
• Maintain effective, confidential and auditable screening records, including risk assessment, consent, results, referrals, colonoscopy reports, pathology-related information, adverse events and follow-up actions.[2][3][11][7]
• Require programme coordinators to track screening tests, outcomes and clinical performance indicators, while facilities and laboratories conduct regular internal monitoring, evaluation and compliance audits.[3]
• Permit Ministry of Health and Prevention inspection and audit of provider records, require cooperation with authorised auditors, and apply sanctions for breaches; healthcare providers, payers and third-party administrators are required to comply with the guideline.[2]
• Use laboratory accreditation and independent quality-assurance testing commissioned by the Ministry of Health and Prevention as external quality mechanisms. Recognised examples include College of American Pathologists, ISO 15189 and Joint Commission International accreditation.[3]
• Monitor participation, colonoscopy volumes, inadequate faecal immunochemical test rates, result turnaround, referral and colonoscopy timeliness, caecal intubation, adenoma and cancer detection, withdrawal time, polyp retrieval, high-grade neoplasia, complications, perforation and time to definitive management.[12]
• Apply acceptable and desirable thresholds of more than 45% and more than 65% for screening participation, more than 90% and more than 95% for caecal intubation, and more than 90% and more than 95% for polyp retrieval.[12]
• Limit inadequate bowel preparation to no more than 10% of examinations.[6][10]
• Monitor unacceptable faecal immunochemical test samples, which must not exceed 3% of kits received, with less than 1% identified as desirable.[7]
• Measure time to participant notification of results, with more than 90% of participants expected to receive results within 15 working days.[7]
• Audit adenoma detection rates for screening colonoscopy, excluding surveillance and repeat endoscopic procedures, and record screening and follow-up colonoscopy caecal intubation separately.[7][12]
• Document photographic or video evidence of examination completion, rectal retroflexion, withdrawal time, instruments used, incomplete procedures and adverse clinical events; retain reports for audit.[10][11][12]
• Review equipment functioning, colonoscope cleansing and infection-control arrangements regularly, with the review available within the endoscopy unit.[4]
• Track urgent referrals for screen-detected colorectal cancer within two weeks, definitive management within 31 days in more than 95% of cases, and deaths attributed to colonoscopy complications within 30 days through electronic notification.[7]
• Monitor post-procedure complications for 30 days and contact patients 24 hours after colonoscopy or on the next working day.[11]
• Re-invite people with negative results at the specified screening intervals, repeat colonoscopy for adenoma according to the pathway, repeat unclear or spoilt faecal immunochemical tests, and refer positive faecal immunochemical tests for follow-up colonoscopy. The extracts specify both a 15-working-day follow-up target and provision of colonoscopy within 31 days.[7][4]
• Support longer-term surveillance through condition-specific colonoscopy and endoscopy intervals for people with family histories, inflammatory bowel disease and hereditary syndromes, and systematically flag eligible cases for future Emirate-level audit.[5][9]

The extracts do not provide a single consolidated reporting timetable, population-wide evaluation schedule or complete indicator dictionary beyond the registry, audit, surveillance and performance requirements described above.[3][5][9][13]

Costing & Financing

Financing is addressed principally through eligibility for reimbursement under the Health Insurance Scheme, determined in accordance with the applicable local insurance laws of each Emirate.[2][3]

• Determine reimbursement eligibility according to Emirate-level insurance legislation rather than a single national payment rule.[2][3]
• Provide no explicit programme budget, unit cost, financial allocation, funding source, resource-mobilisation plan, funding-gap estimate or economic assumption in the supplied extracts.[3][11][7][14][12][4][8][5][9][13]